Breaking Business News | Breaking business news AM | Breaking Business News PM

Gilead stock plummets after disappointing COVID-19 drug trial results published by accident

23 Apr 2020

Shares of Gilead Sciences were down more than 5.5% in midday trading.  

Shares of pharma giant Gilead Sciences fell sharply today after details of a clinical trial for a much-anticipated antiviral drug suggested no immediate benefit for patients diagnosed with COVID-19.

Read the full article here.
This content was originally published by Fast Company. Original publishers retain all rights. It appears here for a limited time before automated archiving. By Fast Company

Covid-19 – Johns Hopkins University

Download brochure

Introduction brochure

What we do, case studies and profiles of some of our amazing team.